Jun-Young Lee
Corporate Officer/Principal at SAMSUNG ELECTRONICS CO., LTD.
Jun-Young Lee active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SAMSUNG ELECTRONICS CO., LTD. | Corporate Officer/Principal | - | - |
Selecxine, Inc. Co Ltd.
 Selecxine, Inc. Co Ltd. BiotechnologyHealth Technology Selecxine, Inc. Co Ltd. is a bio start-up founded in December 2018 in an undisclosed location. The company is based in Seoul, South Korea. The South Korean company specializes in developing monoclonal antibodies using platform technology. Selecxine develops antibodies that bind to specific epitopes on target proteins for modification and amplification of the desired signal from bifunctional biomolecules such as cytokines and cytokine receptors. The company's novel candidate, SLC-3010, is an immune-mediated anti-cancer therapeutic that selectively stimulates anti-tumor immune response. The efficacy of SLC-3010 in eradicating various types of tumors was thoroughly demonstrated through various in vitro and in vivo experiments. Selecxine is actively developing subsequent pipelines based on the well-established in-house platform. The company was founded in 2018, and the CEO is Jun-Young Lee. | Chief Executive Officer | - | - |
Career history of Jun-Young Lee
Training of Jun-Young Lee
| Soongsil University | Undergraduate Degree |
Statistics
International
| South Korea | 4 |
Operational
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Electronic Technology | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SAMSUNG ELECTRONICS CO., LTD. | Electronic Technology |
| Private companies | 1 |
|---|---|
Selecxine, Inc. Co Ltd.
Selecxine, Inc. Co Ltd. BiotechnologyHealth Technology Selecxine, Inc. Co Ltd. is a bio start-up founded in December 2018 in an undisclosed location. The company is based in Seoul, South Korea. The South Korean company specializes in developing monoclonal antibodies using platform technology. Selecxine develops antibodies that bind to specific epitopes on target proteins for modification and amplification of the desired signal from bifunctional biomolecules such as cytokines and cytokine receptors. The company's novel candidate, SLC-3010, is an immune-mediated anti-cancer therapeutic that selectively stimulates anti-tumor immune response. The efficacy of SLC-3010 in eradicating various types of tumors was thoroughly demonstrated through various in vitro and in vivo experiments. Selecxine is actively developing subsequent pipelines based on the well-established in-house platform. The company was founded in 2018, and the CEO is Jun-Young Lee. | Health Technology |
- Stock Market
- Insiders
- Jun-Young Lee
- Experience
